Arovella Therapeutics Limited
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ALA.AX research report →
Price Chart
About the company
Arovella Therapeutics Limited, an Australian biotechnology firm, is dedicated to developing therapeutic solutions for oncology and central nervous system afflictions, operating both domestically and internationally. Its pipeline features several key assets, including ZolpiMist, an oral spray formulation of zolpidem tartrate for the treatment of short-term insomnia, commercially known by brands such as Ambien or Stilnox. The company is also advancing an invariant natural killer T (iNKT) cell therapy platform specifically designed to target blood cancers.
- CEO
- Nicole van der Weerden
- IPO
- 2002
- Employees
- 27
- HQ
- Preston, VIC, AU
Get TickerSpark's AI analysis on ALA.AX
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $78.58M
- P/E
- -11.21
- PEG
- -0.82
- P/S
- 0.00
- P/B
- 5.53
- EV/EBITDA
- -5.79
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -41.83%
- ROIC
- -52.55%
Latest fiscal year · YoY change
- Revenue
- $0-100.0%
- Gross Profit
- $-117,710-186.6%
- Op Income
- $-11,214,596
- Net Income
- $-6,916,453+7.9%
- EPS
- $-0.01+14.7%
- OCF Growth
- +0.3%
- FCF Growth
- +5.4%
- 52W High
- $0.13
- 52W Low
- $0.06
- 50D MA
- $0.06
- 200D MA
- $0.08
- Beta
- 0.12
- RSI (14)
- 57
- Avg Volume
- 729.46K
No earnings-call transcripts are available for ALA.AX yet.
- Free Float
- 75.8%
- Shares Outstanding
- 1.21B
- Float Shares
- 916.89M
Our ALA.AX coverage
Recent articles, reports, and earnings notes.
No research on ALA.AX yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate ALA.AX report →Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.